Does Antidepressant Use Blunt Adaptations to Exercise?
Atslēgvārdi
Abstrakts
Datumi
Pēdējoreiz pārbaudīts: | 06/30/2019 |
Pirmais iesniegtais: | 04/25/2019 |
Paredzētā reģistrācija iesniegta: | 04/28/2019 |
Pirmais izlikts: | 05/01/2019 |
Pēdējais atjauninājums iesniegts: | 07/21/2019 |
Pēdējā atjaunināšana ievietota: | 07/22/2019 |
Faktiskais studiju sākuma datums: | 06/14/2019 |
Paredzamais primārās pabeigšanas datums: | 06/30/2020 |
Paredzamais pētījuma pabeigšanas datums: | 06/30/2020 |
Stāvoklis vai slimība
Iejaukšanās / ārstēšana
Behavioral: Exercise
Fāze
Roku grupas
Roka | Iejaukšanās / ārstēšana |
---|---|
Active Comparator: Control This arm will consist of healthy overweight and obese individuals who are physically inactive and do not have clinically diagnosed depression or depression symptoms. | |
Experimental: Antidpressants This arm will consist of healthy overweight and obese adults who are physically inactive and who are diagnosed with clinical depression and have been taking antidepressant medications for at least 1 year. |
Atbilstības kritēriji
Vecums, kas piemērots studijām | 18 Years Uz 18 Years |
Dzimumi, kas ir piemēroti studijām | All |
Pieņem veselīgus brīvprātīgos | Jā |
Kritēriji | Inclusion Criteria: - Participants will be English language speakers - Male or females between the ages of 18-40. - All genders and ethnicities. - Healthy as assessed by a health history questionnaire (no diagnosed physical diseases or conditions preventing participation in exercise). - Individuals on antidepressants will be recruited if they are consuming selective serotonin reuptake inhibitors (SSRIs) and selective serotonin and norepinephrine reuptake inhibitors (SNRIs) only. Participants will send prescription information after consent has been provided as part of the screening process, including the dose and frequency of medication. - A body mass index (BMI) of 25 or greater is required for inclusion. Exclusion Criteria: - Inability to complete moderate-vigorous exercise. - Taking first generation antidepressant medications or other medications such as monoamine oxidase inhibitors (MAOI). - Other medications, such as medications for attention-deficit hyper-activity disorder or metabolism - Undiagnosed depression that may be unveiled during the screening process. |
Rezultāts
Primārie rezultāti
1. Visceral adipose tissue (VAT) [Change from baseline after 6 weeks.]
2. Waist circumference [Change from baseline after 6 weeks.]
Sekundārie iznākuma mērījumi
1. Aerobic fitness [Change from baseline after 6 weeks.]
2. Blood pressure [Change from baseline after 6 weeks.]
3. Blood glucose [Change from baseline after 6 weeks.]
4. Blood lipid panel [Change from baseline after 6 weeks.]
5. Body mass [Change from baseline after 6 weeks.]
6. Fat mass [Change from baseline after 6 weeks.]
7. Lean mass [Change from baseline after 6 weeks.]
8. Dietary intake [Change from baseline after 6 weeks.]
9. Physical activity [Change from baseline after 6 weeks.]
10. Depression symptoms [Change from baseline after 6 weeks.]